About Vitexel
Vitexel Therapeutics is a UK specialty pharmaceutical company established to develop and commercialise differentiated prescription NSAIDs, led by Oxprofen™.
Our story
Oxprofen builds on drug delivery technology first developed at the University of Oxford and on more than fifteen years of formulation development. Vitexel was formed to take it through development and to market, starting with the US prescription market.
How we work
Vitexel is a focused, asset-light company. A small core team directs an outsourced development programme with established partners in clinical pharmacology, regulatory affairs, API manufacture and formulation.
Team
Marcelo Bravo
Founder and CEO. Four companies founded, two AIM listings, more than £60 million raised.
Chris Hill
Non-Executive Director (proposed). CEO and CFO, Adaptimmune.
Tom Ivings
CFO. Corporate finance
Carlos Velez
US Commercial Adviser. Specialty pharma partnering.
Ann Taylor-Hutchinson
CMC Lead. Oral solid dose development.
Sheryl Caswell
Clinical Development Adviser. Clinical and regulatory strategy.
Partnering enquiries
We welcome conversations with specialty pharmaceutical companies.